Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients.

Alberto Hernando-CalvoA García-AlvarezG VillacampaC OrtizD BodetV García-PatosJ A RecioR DienstmannE Muñoz-Couselo

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2020)

We found that major shifts in dNLR and LDH measures from baseline to cycle 2 measures and shifts from baseline to cycle 2 are significantly associated with OS in MM patients receiving single agent anti-PD1 therapy. Laboratory changes and clinical variables may help optimize prognostic estimates.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
stem cells
bone marrow
mesenchymal stem cells
smoking cessation